Dr. William Williams reports

DATA SAFETY MONITORING BOARD (DSMB) RECOMMENDS CONTINUING BRIACELL'S PHASE 3 METASTATIC BREAST CANCER STUDY

An independent data safety monitoring board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from Briacell Therapeutics Corp.'s pivotal phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

Following its review, the DSMB raised no safety or other clinical concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. Briacell's continuing pivotal phase 3 study is being conducted under fast-track designation granted by the U.S. Food and Drug Administration (FDA), reflecting the significant unmet medical need in metastatic breast cancer.

"We are very encouraged by the DSMB's seventh consecutive positive recommendation to continue Briacell's pivotal phase 3 Bria-ABC study," said Dr. William V. Williams, president and chief executive officer of Briacell. "This milestone represents continued progress in developing Briacell's novel immunotherapies for patients with urgent unmet medical needs."

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.